WebApr 11, 2024 · One ovarian cancer trial has a bevacizumab combo, and the others are monotherapies. A second asset, STRO-001, is a CD74 ADC targeting two indications, … Web2 days ago · As part of the phase 3 GLORIOSA study (NCT05445778), a clinical trial is evaluating the safety and efficacy of the antibody drug conjugate (ADC) mirvetuximab soravtansine (Elahere) as maintenance therapy for patients with folate receptor-alpha (FRα)-positive recurrent platinum-sensitive ovarian cancer. 1 In the multicenter, open-label …
Phase 3 Trial Further Examines Maintenance Mirvetuximab …
WebApr 11, 2024 · AbstractPurpose:. Claudin-6 (CLDN6) is expressed at elevated levels in multiple human cancers including ovarian and endometrial malignancies, with little or no … WebJun 2, 2024 · Meeting Abstract 2024 ASCO Annual Meeting I Gynecologic Cancer Safety and efficacy of MORAb-202 in patients (pts) with platinum-resistant ovarian cancer (PROC): Results from the expansion part of a phase 1 trial. Shin Nishio , Mayu Yunokawa , Koji Matsumoto , Kazuhiro Takehara , Kosei Hasegawa , Yasuyuki Hirashima , ... Show … the hyatt in key west florida
Frontiers Apparent diffusion coefficient histogram analysis for ...
WebNov 14, 2024 · On November 14, 2024, the Food and Drug Administration granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc.) for … WebNov 15, 2024 · The ADC comprises an FRα-binding antibody, a cell-surface protein which is greatly expressed in ovarian cancer, as well as the maytansinoid payload DM4. Elahere … WebNov 15, 2024 · The ADC comprises an FRα-binding antibody, a cell-surface protein which is greatly expressed in ovarian cancer, as well as the maytansinoid payload DM4. Elahere is said to be the first ADC to receive FDA approval for platinum-resistant disease. ImmunoGen president and CEO Mark Enyedy said: “With an indication for use regardless of prior ... the hyatt in key west